This is a well capitalised, science led biotechnology company developing highly innovative therapeutics within oncology and vaccine platforms, with emerging activity in mRNA based technologies. The organisation is backed by top tier investors and supported by a leadership team with an established track record of building and advancing successful biotech companies. Scientific rigour, pace and quality of execution are central to the culture.

As programmes progress into first in human clinical development, the company is seeking a Senior Medical Director to take hands on ownership of early phase clinical strategy and execution.

Role Overview

The Senior Medical Director will play a critical hands on role in leading first in human and Phase 1 clinical programmes. The position is suited to a clinically grounded development leader who remains close to protocol design, safety oversight and emerging data, and who thrives in a science driven, early stage environment.

Required Experience

• Medical degree with specialist training and significant experience in clinical development

• Strong background in oncology clinical development

• Demonstrated hands on leadership of first in human and Phase 1 clinical trials

• Proven experience designing and authoring Phase 1 protocols including SAD, MAD and dose escalation designs

• Experience acting as medical monitor with direct responsibility for patient safety and real time decision making

• Ability to translate preclinical and translational data into clinically meaningful early development strategies

• Experience working closely with CROs, investigators and internal multidisciplinary teams

• Track record of operating effectively in biotech or lean development environments

Desired Experience

• Experience in therapeutic vaccines or cancer vaccine development

• Exposure to mRNA based platforms or nucleic acid therapeutics

• Experience supporting regulatory interactions related to early phase development including IND or CTA submissions

• Experience presenting early clinical data to senior leadership, investors or external stakeholders

• Prior involvement in expansion cohorts or proof of mechanism studies in oncology